Latest News
All Times Eastern
- Bond yields steady before payrolls after week of big price gains
- These analysts say the office and apartment building worries after NYCB are like Groundhog Day — but do concede one issue
- Car loaded with gas in Kenya explodes and sets off inferno that injures more than 270, kills at least 33
- Barron's Energy Stocks Have Struggled. Why They Shine as Dividend Payers.
- Barron's Philip Morris Stock Stands to Get a Boost From Earnings
- Barron's Brazil Is Having a Great Time. 5 Stocks to Play.
- Barron's Boeing’s Troubles Aren’t Going Away. How to Profit From Its Problems.
- Barron's The 6% Commission for Home Sales Is Under Attack. Inside the Fight to Keep It Alive.
- Prosecutors weigh perjury charge for ex-Trump CFO Allen Weisselberg over civil fraud trial testimony
- Shares of China’s Landsea Green rise on plan to buy Texas homebuilder for $185 million
to be replaced
Amgen Inc.
AMGNUS
$
-0.96
-0.30%
Premarket
$
323.60
Before Hours Volume:
66
| Close | Chg | Chg % |
|---|---|---|
| $324.56 | 10.30 | 3.28% |
Volume: 3.88M
65 Day Avg: 2.44M
313.70
Day Range
324.82
211.71
52 Week Range
324.82
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
AMGN Overview
Key Data
- Open $314.50
- Day Range 313.70 - 324.82
- 52 Week Range 211.71 - 324.82
- Market Cap $168.19B
- Shares Outstanding 535.18M
- Public Float 533.99M
- Beta 0.63
- Rev. per Employee $1.057M
- P/E Ratio 23.08
- EPS $14.06
- Yield 2.77%
- Dividend $2.25
- Ex-Dividend Date Feb 15, 2024
- Short Interest 8.84M 01/12/24
- % of Float Shorted 1.66%
- Average Volume 2.44M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 27
Full Ratings
Recent News
Biotech and Pharma Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.
Is Amgen Stock a Buy Now?
on Motley Fool
Invest with Confidence: Intrinsic Value Unveiled of Amgen Inc
Invest with Confidence: Intrinsic Value Unveiled of Amgen Inc
on GuruFocus.com
Amgen Options Trading: A Deep Dive into Market Sentiment
on Benzinga.com
Expert Outlook: Amgen Through The Eyes Of 11 Analysts
on Benzinga.com
Is Amgen a Good Dividend Stock to Buy Right Now?
on Motley Fool
Should You Buy the Dogs of the Dow in 2024?
on Motley Fool
P/E Ratio Insights for Amgen
on Benzinga.com
Analysts’ Top Healthcare Picks: Amgen (AMGN), Argenx Se (ARGX)
on TipRanks.com
Amgen Inc.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Johnson & Johnson | $382.52B | |
| Pfizer Inc. | $152.9B | |
| Novo Nordisk A/S | kr.3.47T | |
| AbbVie Inc. | $290.25B | |
| AstraZeneca PLC ADR | $207.28B | |
| AstraZeneca PLC | £162.77B | |
| Moderna Inc. | $38.53B | |
| Gilead Sciences Inc. | $97.52B | |
| Regeneron Pharmaceuticals Inc. | $102.71B | |
| Lonza Group AG | CHF31.56B |